Acta Allergologica
Journal
-
- Overview
-
- Identity
-
- View All
-
Overview
publication venue for
-
Myeloid dendritic cells type 2 in allergic asthma
2013
-
The effect of IVX‐0142, a heparin‐derived hypersulfated disaccharide, on the allergic airway responses in asthma
2008
-
Pharmacologic modulation of airway inflammation
1998
-
Assessing cost‐effectiveness in asthma care: building an economic model to study the impact of alternative intervention strategies
1993
-
Cells and mediators in bronchoalveolar lavage of asthmatic patients: the example of eosinophilic inflammation
1993
-
Clinical significance of measuring levels of sputum and serum ECP and serum IL‐5 in bronchial asthma
1993
-
Functional and phenotypic characteristics of bronchial epithelial cells obtained by brushing from asthmatic and normal subjects
1993
-
Impact of monitoring inflammation on the management of adult asthmatic patients
1993
-
Pathophysiology of asthma
1993
-
The definition and diagnosis of asthma
1993
-
T‐cells and endothelial cells in asthma
1993
-
Reply to Correspondence: The Bronchodilator and Anti-Inflammatory Effect of Long-Acting Muscarinic Antagonists in Asthma: An EAACI Position Paper.
2025
-
Validity, reliability and responsiveness of digital visual analogue scales for chronic spontaneous urticaria monitoring: A CRUSE® mobile health study..
80:750-761.
2025
-
Long-term safety and efficacy of garadacimab for preventing hereditary angioedema attacks: Phase 3 open-label extension study..
80:545-556.
2025
-
The Bronchodilator and Anti-Inflammatory Effect of Long-Acting Muscarinic Antagonists in Asthma: An EAACI Position Paper..
80:380-394.
2025
-
Up-dosing of reslizumab in severe asthmatics with persistent sputum eosinophilia: A feasibility study..
80:605-608.
2025
-
Allergic Reactivity and Memory Occur Independently of Sequential Switching Through IgG1.
2025
-
Development and acceptability of a decision-aid for food allergy oral immunotherapy in children..
80:205-214.
2025
-
EAACI guidelines on the management of IgE-mediated food allergy..
80:14-36.
2025
-
Efficacy and safety of intranasal medications for allergic rhinitis: Network meta-analysis..
80:94-105.
2025
-
Food Allergy Genetics and Epigenetics: A Review of Genome-Wide Association Studies..
80:106-131.
2025
-
Allergic inflammation triggers dyslipidemia via IgG signalling.
79:2680-2699.
2024
-
Comparison of upper and lower airway expression of SARS‐COV‐2 receptors in allergic asthma.
79:2856-2858.
2024
-
Response of sputum periostin to anti‐T2 biologics treatment in severe asthma.
79:2842-2844.
2024
-
Sputum cytokines associated with raised FeNO after anti‐IL5 biologic therapy in severe asthma.
79:2244-2247.
2024
-
Patients' values and preferences for health states in allergic rhinitis—An artificial intelligence supported systematic review.
79:1812-1830.
2024
-
Tezepelumab in patients with allergic and eosinophilic asthma.
79:1134-1145.
2024
-
Core Outcome Set for IgE‐mediated food allergy clinical trials and observational studies of interventions: International Delphi consensus study ‘COMFA’.
79:977-989.
2024
-
Antigens localized to B‐cell follicles are protected from proteases: Implications for allergy and allergen immunotherapy.
79:537-539.
2024
-
Effect of dupilumab on sputum eosinophils in patients with moderate‐to‐severe asthma.
79:509-513.
2024
-
Phase 1 trial supports safety and mechanism of action of peptide immunotherapy for peanut allergy.
79:485-498.
2024
-
Systematic review and meta‐analyses on the accuracy of diagnostic tests for IgE‐mediated food allergy.
79:324-352.
2024
-
Next generation health guidelines: The role of real‐life data in evidence‐based medicine.
79:12-14.
2024
-
EAACI guidelines on the diagnosis of IgE‐mediated food allergy.
78:3057-3076.
2023
-
Eosinophils—from cradle to grave.
78:3077-3102.
2023
-
Meglumine gadoterate induces immunoglobulin‐independent human mast cell activation via MRGPRX2.
78:3255-3258.
2023
-
Protein expression of SARS‐CoV‐2 receptors ACE2 and TMPRSS2 in allergic airways after allergen challenge.
78:3010-3013.
2023
-
UCRAID (Ukrainian Citizen and refugee electronic support in Respiratory diseases, Allergy, Immunology and Dermatology) action plan.
78:2581-2595.
2023
-
Mapping the way to strengthening epithelial barriers: Neuronal circuits in mucus regulation.
78:2799-2801.
2023
-
Global, regional, and national burden of allergic disorders and their risk factors in 204 countries and territories, from 1990 to 2019: A systematic analysis for the Global Burden of Disease Study 2019.
78:2232-2254.
2023
-
Patient‐centered digital biomarkers for allergic respiratory diseases and asthma: The ARIA‐EAACI approach – ARIA‐EAACI Task Force Report.
78:1758-1776.
2023
-
The future of food allergy: Challenging existing paradigms of clinical practice.
78:1847-1865.
2023
-
Rhinitis associated with asthma is distinct from rhinitis alone: The ARIA‐MeDALL hypothesis.
78:1169-1203.
2023
-
Consistent trajectories of rhinitis control and treatment in 16,177 weeks: The MASK‐air® longitudinal study.
78:968-983.
2023
-
Sounding the alarmins—The role of alarmin cytokines in asthma.
78:402-417.
2023
-
The maternal prenatal and offspring early‐life gut microbiome of childhood asthma phenotypes.
78:418-428.
2023
-
Diagnostic accuracy of vaccine and vaccine excipient testing in the setting of allergic reactions to COVID‐19 vaccines: A systematic review and meta‐analysis.
78:71-83.
2023
-
The impact of type 2 immunity and allergic diseases in atherosclerosis.
77:3249-3266.
2022
-
Comparison of rhinitis treatments using MASK‐air® data and considering the minimal important difference.
77:3002-3014.
2022
-
Behavioural patterns in allergic rhinitis medication in Europe: A study using MASK‐air® real‐world data.
77:2699-2711.
2022
-
Development and validation of combined symptom‐medication scores for allergic rhinitis*.
77:2147-2162.
2022
-
EAACI position paper on the clinical use of the bronchial allergen challenge: Unmet needs and research priorities.
77:1667-1684.
2022
-
Group 2 innate lymphoid cells in patients with nonasthmatic eosinophilic bronchitis.
77:649-652.
2022
-
Local inflammation enables a basophil‐neuronal circuITCH in atopic dermatitis.
77:708-710.
2022
-
One hundred and ten years of Allergen Immunotherapy: A journey from empiric observation to evidence.
77:454-468.
2022
-
The food, the bug, and the ugly: A recipe for food‐induced gut pain.
77:334-336.
2022
-
Detecting immunoglobulins in processed sputa.
76:3798-3800.
2021
-
Notch4, uncovering an immunomodulator in allergic asthma.
76:3852-3854.
2021
-
Technical standards in allergen exposure chambers worldwide – an EAACI Task Force Report.
76:3589-3612.
2021
-
Medical algorithms: Approach to adult asthma exacerbations.
76:3556-3559.
2021
-
Management of anaphylaxis due to COVID‐19 vaccines in the elderly.
76:2952-2964.
2021
-
Allergen immunotherapy: The growing role of observational and randomized trial “Real‐World Evidence”.
76:2663-2672.
2021
-
Effect of anti‐IL‐5 biologics on weight and body mass index.
76:2913-2916.
2021
-
Effect of intranasal corticosteroid treatment on allergen‐induced changes in group 2 innate lymphoid cells in allergic rhinitis with mild asthma.
76:2797-2808.
2021
-
Differentiation of COVID‐19 signs and symptoms from allergic rhinitis and common cold: An ARIA‐EAACI‐GA2LEN consensus.
76:2354-2366.
2021
-
Enlightening human B‐cell diversity.
76:2644-2646.
2021
-
Comparison of house dust mite sensitization profiles in allergic adults from Canada, Europe, South Africa and USA.
76:2177-2188.
2021
-
First contact: Serum amyloid A and pattern recognition in Th2 immunity.
76:2309-2311.
2021
-
IL‐13 signature in severe adult asthmatics with airway neutrophilia: A new endotype to treat!.
76:1964-1966.
2021
-
Direct and indirect bronchoprovocation tests in dose‐response studies of inhaled corticosteroids: Past, present, and future directions.
76:1679-1692.
2021
-
Immunological changes in peripheral blood following nasal allergen challenge in subjects with allergic rhinitis pre‐ and post‐peptide immunotherapy: An open‐label clinical study.
76:1907-1911.
2021
-
The global burden of illness of peanut allergy: A comprehensive literature review.
76:1367-1384.
2021
-
Monitoring eosinophils to guide therapy with biologics in asthma: does the compartment matter?.
76:1294-1297.
2021
-
ARIA‐EAACI statement on asthma and COVID‐19 (June 2, 2020).
76:689-697.
2021
-
Cabbage and fermented vegetables: From death rate heterogeneity in countries to candidates for mitigation strategies of severe COVID‐19.
76:735-750.
2021
-
Dupilumab, severe asthma airway responses, and SARS‐CoV‐2 serology.
76:957-958.
2021
-
Modeling the conversion between specific IgE test platforms for nut allergens in children and adolescents.
76:831-841.
2021
-
Obituary: Anthony Barrington Kay (1939‐2020).
76:969-969.
2021
-
ARIA digital anamorphosis: Digital transformation of health and care in airway diseases from research to practice.
76:168-190.
2021
-
Asthma exacerbations on benralizumab are largely non‐eosinophilic.
76:375-379.
2021
-
EAACI Biologicals Guidelines—Recommendations for severe asthma.
76:14-44.
2021
-
Thinking small: Zinc sensing by the gut epithelium.
76:411-413.
2021
-
A compendium answering 150 questions on COVID‐19 and SARS‐CoV‐2.
75:2503-2541.
2020
-
Immunology of COVID‐19: Mechanisms, clinical outcome, diagnostics, and perspectives—A report of the European Academy of Allergy and Clinical Immunology (EAACI).
75:2445-2476.
2020
-
Intranasal corticosteroids in allergic rhinitis in COVID‐19 infected patients: An ARIA‐EAACI statement.
75:2440-2444.
2020
-
Single‐cell RNA analysis: Guiding the treatment of DiHS/DRESS.
75:2713-2715.
2020
-
Phenotype consensus is required to enable large‐scale genetic consortium studies of food allergy.
75:2383-2387.
2020
-
The neuroimmunological toll of nutrient absorption.
75:2415-2417.
2020
-
Exon 8 KIT mutation and pulmonary eosinophilia.
75:2094-2096.
2020
-
Mining the infant gut microbiota for therapeutic targets against atopic disease.
75:2065-2068.
2020
-
Sputum and serum immunoglobulins in adult asthmatics with recurrent respiratory tract infections.
75:2105-2108.
2020
-
Cord blood hemopoietic cell receptor expression is associated with early life atopic risk and lung function.
75:1762-1765.
2020
-
Correlation between work impairment, scores of rhinitis severity and asthma using the MASK‐air®App.
75:1672-1688.
2020
-
Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: A systematic review for the EAACI Guidelines ‐ recommendations on the use of biologicals in severe asthma.
75:1043-1057.
2020
-
Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines ‐ recommendations on the use of biologicals in severe asthma.
75:1023-1042.
2020
-
Efficacy and safety of treatment with dupilumab for severe asthma: A systematic review of the EAACI guidelines—Recommendations on the use of biologicals in severe asthma.
75:1058-1068.
2020
-
The presence of Aspergillus fumigatus in asthmatic airways is not clearly related to clinical disease severity.
75:1146-1154.
2020
-
Follicular T cells: From stability to failure.
75:1006-1007.
2020
-
New paradigm in asthma management: Switching between biologics!.
75:743-745.
2020
-
Drug‐induced IgG‐neutrophil‐mediated anaphylaxis in humans: Uncovered!.
75:484-485.
2020
-
Mechanisms and therapeutic strategies for non‐T2 asthma.
75:311-325.
2020
-
Extract and component‐specific sensitization patterns in Canadian moderate‐to‐severe preschool asthmatics.
74:2519-2521.
2019
-
2019 ARIA Care pathways for allergen immunotherapy.
74:2087-2102.
2019
-
Modulation of CRTh2 expression on allergen‐specific T cells following peptide immunotherapy.
74:2157-2166.
2019
-
Severe asthma: Entering an era of new concepts and emerging therapies: Highlights of the 4th international severe asthma forum, Madrid, 2018.
74:2244-2248.
2019
-
Legends of allergy/immunology: A. Barry Kay.
74:1588-1590.
2019
-
ARIA pharmacy 2018 “Allergic rhinitis care pathways for community pharmacy”.
74:1219-1236.
2019
-
Effect of sex on group 2 innate lymphoid cells in the airways of mild and severe asthmatics.
74:1397-1400.
2019
-
Rapid quantification of sputum eosinophil peroxidase on a lateral flow test strip.
74:1176-1178.
2019
-
Much ado about Biologicals: Highlights of the Master Class on Biologicals, Prague, 2018.
74:837-840.
2019
-
IgG1+ B‐cell immunity predates IgE responses in epicutaneous sensitization to foods.
74:165-175.
2019
-
Human milk oligosaccharide profiles and food sensitization among infants in the CHILD Study.
73:2070-2073.
2018
-
Daily allergic multimorbidity in rhinitis using mobile technology: A novel concept of the MASK study.
73:1622-1631.
2018
-
Sputum cytology during late‐phase responses to inhalation challenge with different allergens.
73:1470-1478.
2018
-
The Allergic Rhinitis and its Impact on Asthma (ARIA) score of allergic rhinitis using mobile technology correlates with quality of life: The MASK study.
73:505-510.
2018
-
Perspectives in allergen immunotherapy: 2017 and beyond.
73:5-23.
2018
-
Vitamin D supplementation in primary allergy prevention: Systematic review of randomized and non‐randomized studies.
73:37-49.
2018
-
Positioning the principles of precision medicine in care pathways for allergic rhinitis and chronic rhinosinusitis – A EUFOREA‐ARIA‐EPOS‐AIRWAYS ICP statement.
72:1297-1305.
2017
-
Allergen exposure chambers: harmonizing current concepts and projecting the needs for the future – an EAACI Position Paper.
72:1035-1042.
2017
-
Novel approaches and perspectives in allergen immunotherapy.
72:1022-1034.
2017
-
A dual CysLT1/2 antagonist attenuates allergen‐induced airway responses in subjects with mild allergic asthma.
71:1721-1727.
2016
-
Global perceptions of food allergy thresholds in 16 countries.
71:1081-1085.
2016
-
Emotional and behavioral problems in adolescents and young adults with food allergy.
71:532-540.
2016
-
Histone deacetylase activity and recurrent bacterial bronchitis in severe eosinophilic asthma.
71:571-575.
2016
-
Nasal and pharyngeal eosinophil peroxidase levels in adults with poorly controlled asthma correlate with sputum eosinophilia.
71:567-570.
2016
-
Treatment with anti‐cytokine monoclonal antibodies can potentiate the target cytokine rather than neutralize its activity.
71:283-285.
2016
-
MACVIA-ARIA Sentinel NetworK for allergic rhinitis (MASK-rhinitis): the new generation guideline implementation.
70:1372-1392.
2015
-
Treatment with anti-OX40L or anti-TSLP does not alter the frequency of T regulatory cells in allergic asthmatics.
70:1505-1508.
2015
-
Comprehensive metabolomics identifies the alarmin uric acid as a critical signal for the induction of peanut allergy.
70:495-505.
2015
-
Safety of sublingual immunotherapy Timothy grass tablet in subjects with allergic rhinitis with or without conjunctivitis and history of asthma.
70:302-309.
2015
-
Once‐daily fluticasone furoate 50 mcg in mild‐to‐moderate asthma: a 24‐week placebo‐controlled randomized trial.
69:1522-1530.
2014
-
Global Allergy Forum and Second Davos Declaration 2013 Allergy: Barriers to cure - challenges and actions to be taken.
69:978-982.
2014
-
EAACI position statement on asthma exacerbations and severe asthma.
68:1520-1531.
2013
-
Eosinophil peroxidase in sputum represents a unique biomarker of airway eosinophilia.
68:1177-1184.
2013
-
Erratum.
67:712-712.
2012
-
Functional rather than immunoreactive levels of IgG4 correlate closely with clinical response to grass pollen immunotherapy.
67:217-226.
2012
-
Comparing school environments with and without legislation for the prevention and management of anaphylaxis.
67:131-137.
2012
-
Dose-response effects of TPI ASM8 in asthmatics after allergen.
66:1242-1248.
2011
-
Intestinal epithelial cells express galectin-9 in patients with food allergy that plays a critical role in sustaining allergic status in mouse intestine.
66:1038-1046.
2011
-
Sputum inflammatory cells and allergen-induced airway responses in allergic asthmatic subjects.
66:1075-1080.
2011
-
How to design and evaluate randomized controlled trials in immunotherapy for allergic rhinitis: an ARIA-GA2LEN statement.
66:765-774.
2011
-
Immunotherapy with peptides.
66:784-791.
2011
-
Grading quality of evidence and strength of recommendations in clinical practice guidelines part 3 of 3. The GRADE approach to developing recommendations.
66:588-595.
2011
-
Effect of asthma treatment on fitness, daily activity and body composition in children with asthma.
65:1464-1471.
2010
-
Geographical variations in the prevalence of atopic sensitization in six study sites across Canada.
65:1404-1413.
2010
-
Lung involvement in Churg–Strauss syndrome as related to the activity of the disease.
65:1484-1485.
2010
-
Development and implementation of guidelines in allergic rhinitis – an ARIA‐GA2LEN paper.
65:1212-1221.
2010
-
Management of anaphylaxis in primary care: Canadian expert consensus recommendations.
65:1082-1092.
2010
-
Heart involvement detected by magnetic resonance in a patient with Churg–Strauss syndrome, mimicking severe asthma exacerbation.
65:1063-1064.
2010
-
Gaps in anaphylaxis management at the level of physicians, patients, and the community: a systematic review of the literature.
65:435-444.
2010
-
Sub‐lingual Immunotherapy: World Allergy Organization Position Paper 2009.
64:1-59.
2009
-
The CONSORT statement checklist in allergen‐specific immunotherapy: a GA2LEN paper.
64:1737-1745.
2009
-
EAACI/GA2LEN/EDF/WAO guideline: definition, classification and diagnosis of urticaria.
64:1417-1426.
2009
-
EAACI/GA²LEN/EDF/WAO guideline: management of urticaria.
64:1427-1443.
2009
-
Efficacy of desloratadine in intermittent allergic rhinitis: a GA2LEN study.
64:1516-1523.
2009
-
GA2LEN (Global Allergy and Asthma European Network) addresses the allergy and asthma ‘epidemic’.
64:969-977.
2009
-
Differential effects of skin nerves on allergic skin inflammation.
64:496-497.
2009
-
Grading quality of evidence and strength of recommendations in clinical practice guidelines: Part 2 of 3. The GRADE approach to grading quality of evidence about diagnostic tests and strategies.
64:1109-1116.
2009
-
Grading quality of evidence and strength of recommendations in clinical practice guidelines: part 1 of 3. An overview of the GRADE approach and grading quality of evidence about interventions.
64:669-677.
2009
-
Allergic rhinitis management pocket reference 2008*.
63:990-996.
2008
-
Aspirin tolerance and leukotriene biosynthesis in Churg‐Strauss syndrome.
63:949-950.
2008
-
Important research questions in allergy and related diseases: nonallergic rhinitis: a GA2LEN paper.
63:842-853.
2008
-
Allergic Rhinitis and its Impact on Asthma (ARIA) 2008*.
63:8-160.
2008
-
Consensus statements, evidence‐based medicine and guidelines in allergic diseases.
63:1-4.
2008
-
Indacaterol provides sustained 24 h bronchodilation on once‐daily dosing in asthma: a 7‐day dose‐ranging study.
63:103-111.
2008
-
Methodology for development of the Allergic Rhinitis and its Impact on Asthma Guideline 2008 update.
63:38-46.
2008
-
Circulating myeloid and plasmacytoid dendritic cells after allergen inhalation in asthmatic subjects.
62:1139-1145.
2007
-
The allergen bronchoprovocation model: an important tool for the investigation of new asthma anti‐inflammatory therapies.
62:1101-1110.
2007
-
Development and validation of an electronic version of the Rhinoconjunctivitis Quality of Life Questionnaire.
62:1091-1093.
2007
-
Airway expression of calcitonin gene‐related peptide in T‐cell peptide‐induced late asthmatic reactions in atopics.
62:495-503.
2007
-
Peptide immunotherapy for allergic diseases.
62:325-331.
2007
-
GINA guidelines on asthma and beyond*.
62:102-112.
2007
-
Effects of intranasal fluticasone and salmeterol on allergen‐induced nasal responses.
61:731-736.
2006
-
Anti‐inflammatory effects of once daily low dose inhaled ciclesonide in mild to moderate asthmatic patients.
61:537-542.
2006
-
The effect of Fel d 1‐derived T‐cell peptides on upper and lower airway outcome measurements in cat‐allergic subjects.
60:1269-1274.
2005
-
Continuing Medical Education: an international reality.
60:739-742.
2005
-
In memoriam.
60:546-547.
2005
-
Maintenance of asthma control by once‐daily inhaled ciclesonide in adults with persistent asthma.
60:330-337.
2005
-
Pharmacia Allergy Research Foundation and its Award for Young Scientists in Allergy Research.
60:269-270.
2005
-
The links between allergen skin test sensitivity, airway responsiveness and airway response to allergen.
60:56-59.
2005
-
Cat allergen peptide immunotherapy reduces CD4+ T cell responses to cat allergen but does not alter suppression by CD4+ CD25+ T cells: a double‐blind placebo‐controlled study.
59:1097-1101.
2004
-
The ARIA/EAACI criteria for antihistamines: an assessment of the efficacy, safety and pharmacology of desloratadine.
59:4-16.
2004
-
The promise of and problems with evidence‐based medicine for paediatric asthma management.
57:5-14.
2002
-
Anti‐T‐cell strategies in the treatment of allergic disease.
57:20-23.
2002
-
Can the standard gamble and rating scale be used to measure quality of life in rhinoconjunctivitis? Comparison with the RQLQ and SF‐36.
57:201-206.
2002
-
Selective upregulation of a functional β7 integrin on differentiating eosinophils.
55:865-872.
2000
-
IL‐12 regulates bone marrow eosinophilia and airway eotaxin levels induced by airway allergen exposure.
55:749-756.
2000
-
The nose, the lung and the bone marrow in allergic inflammation.
54:73-80.
1999
-
Circulating eosinophil/basophil progenitors and nasal mucosal cytokines in seasonal allergic rhinitis.
54:212-219.
1999
-
The clinical expression of allergy in the lungs.
54:7-14.
1999
-
The role of shock organs in influencing the clinical expression of allergy.
54:3-6.
1999
-
Hemopoietic progenitors and cytokines in allergic inflammation.
53:22-26.
1998
-
Retinoic acid modulation of induced basophil differentiation.
52:1201-1206.
1997
-
Quality of life in adults and children with asthma and rhinitis.
52:971-977.
1997
-
A comparison of the efficacy and safety of inhaled corticosteroids in asthma.
52:1-34.
1997
-
The role of the bone marrow in allergy and asthma.
51:141-148.
1996
-
Urticaria from allergy to a purified human anti‐Rh antibody preparation.
50:981-983.
1995
-
Microenvironmental influences on inflammatory cell differentiation.
50:25-28.
1995
-
Comparative Therapeutic Studies with Tilavist.
50:23-29.
1995
-
The increased number of epithelial mast cells in nasal polyps and adjacent turbinates is not allergy‐dependent.
45:370-374.
1990
Identity
International Standard Serial Number (ISSN)
Electronic International Standard Serial Number (EISSN)